Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART THREE)
Question
What questions remain unanswered and what future studies are planned to assess resistance mechanisms to chimeric antigen receptor (CAR) T-cells?
Speaker Disclosure: Marco Ruella discloses research support from Abclon, nanoString and Beckman-Coulter; advisory board membership from Abclon, Bayer, CART Tech, UPenn (partly licensed to Novartis), Tmunity, viTToria biotherapeutics, GSK and Sana; consultancy from nanoString and BMS and is the scientific founder of viTToria biotherapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
